Microcide, Pfizer deal

The companies entered into a five-year collaboration to discover drugs to treat resistant bacterial infections. The collaboration will use Microcide's "essential gene" targeting capability, which identifies an estimated 5-10 percent of genes essential to a bacterium's survival, and its target screening technologies. ...